Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Biodesix (BDSX) Shares Issued (2019 - 2026)

Biodesix filings provide 8 years of Shares Issued readings, the most recent being $1000.0 for Q1 2026.

On a quarterly basis, Shares Issued changed N/A to $1000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $7.3 million, a N/A change, with the full-year FY2025 number at $7.3 million, up 29180.0% from a year prior.
Shares Issued hit $1000.0 in Q1 2026 for Biodesix, down from $2.3 million in the prior quarter.
In the past five years, Shares Issued ranged from a high of $55.0 million in Q2 2024 to a low of -$55.6 million in Q3 2024.
Median Shares Issued over the past 5 years was $1.7 million (2022), compared with a mean of $5.4 million.
Biggest five-year swings in Shares Issued: skyrocketed 138473.33% in 2022 and later crashed 463.44% in 2024.
Biodesix's Shares Issued stood at $41.6 million in 2022, then crashed by 70.65% to $12.2 million in 2023, then crashed by 99.95% to $6000.0 in 2024, then soared by 38566.67% to $2.3 million in 2025, then crashed by 99.96% to $1000.0 in 2026.
The last three reported values for Shares Issued were $1000.0 (Q1 2026), $2.3 million (Q4 2025), and $5.0 million (Q3 2025) per Business Quant data.